Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Editing | 12 | 2025 | 234 | 3.740 |
Why?
|
| CRISPR-Cas Systems | 11 | 2025 | 315 | 2.660 |
Why?
|
| Immunotherapy, Adoptive | 13 | 2026 | 948 | 2.150 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2025 | 239 | 2.000 |
Why?
|
| T-Lymphocytes | 17 | 2026 | 1712 | 1.910 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2026 | 498 | 1.520 |
Why?
|
| Genetic Therapy | 5 | 2026 | 714 | 1.250 |
Why?
|
| CD3 Complex | 2 | 2025 | 94 | 1.070 |
Why?
|
| Adoptive Transfer | 3 | 2025 | 235 | 1.020 |
Why?
|
| Killer Cells, Natural | 3 | 2025 | 352 | 0.970 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 1267 | 0.830 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 90 | 0.800 |
Why?
|
| Hematologic Neoplasms | 1 | 2026 | 311 | 0.760 |
Why?
|
| Streptococcus pyogenes | 1 | 2018 | 83 | 0.550 |
Why?
|
| Cell Movement | 1 | 2022 | 868 | 0.550 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 684 | 0.540 |
Why?
|
| Genomics | 1 | 2023 | 1612 | 0.440 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2025 | 26 | 0.410 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2025 | 541 | 0.410 |
Why?
|
| Tacrolimus | 2 | 2020 | 102 | 0.310 |
Why?
|
| Animals | 14 | 2026 | 33773 | 0.290 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2025 | 143 | 0.290 |
Why?
|
| Neuroblastoma | 3 | 2025 | 543 | 0.280 |
Why?
|
| Humans | 30 | 2026 | 130241 | 0.280 |
Why?
|
| Mice | 10 | 2025 | 18190 | 0.270 |
Why?
|
| Cell Line, Tumor | 7 | 2026 | 3705 | 0.260 |
Why?
|
| Gene Transfer Techniques | 2 | 2026 | 344 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2023 | 57 | 0.250 |
Why?
|
| B7-H1 Antigen | 2 | 2025 | 130 | 0.240 |
Why?
|
| Myeloblastin | 1 | 2025 | 18 | 0.230 |
Why?
|
| HLA-A2 Antigen | 1 | 2025 | 25 | 0.220 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2025 | 110 | 0.220 |
Why?
|
| Autoantigens | 1 | 2025 | 100 | 0.220 |
Why?
|
| Osteoclasts | 1 | 2025 | 71 | 0.220 |
Why?
|
| Lymphocyte Activation | 2 | 2025 | 632 | 0.220 |
Why?
|
| Plasma Cells | 1 | 2024 | 54 | 0.210 |
Why?
|
| Neoplasms | 3 | 2025 | 2951 | 0.210 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2024 | 271 | 0.210 |
Why?
|
| Osteogenesis | 1 | 2025 | 180 | 0.210 |
Why?
|
| Hydrogels | 1 | 2024 | 91 | 0.200 |
Why?
|
| Lymphoma, B-Cell | 1 | 2025 | 145 | 0.200 |
Why?
|
| Cell Engineering | 1 | 2023 | 21 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 706 | 0.190 |
Why?
|
| Immunologic Memory | 1 | 2024 | 197 | 0.190 |
Why?
|
| Prosthesis-Related Infections | 1 | 2025 | 186 | 0.190 |
Why?
|
| Cytosine | 1 | 2022 | 56 | 0.180 |
Why?
|
| Antigens, CD19 | 2 | 2021 | 188 | 0.180 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2023 | 137 | 0.180 |
Why?
|
| Cytokines | 2 | 2025 | 1341 | 0.180 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 130 | 0.180 |
Why?
|
| Interferon-gamma | 2 | 2025 | 550 | 0.170 |
Why?
|
| Genome | 1 | 2023 | 453 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2022 | 441 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 290 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 25 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2021 | 155 | 0.160 |
Why?
|
| Drug Resistance | 1 | 2020 | 240 | 0.150 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 657 | 0.150 |
Why?
|
| PAX5 Transcription Factor | 1 | 2019 | 16 | 0.150 |
Why?
|
| Antigens, CD7 | 1 | 2017 | 11 | 0.130 |
Why?
|
| Interleukin-7 | 1 | 2017 | 46 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 154 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 980 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2022 | 759 | 0.130 |
Why?
|
| Leukocyte Common Antigens | 1 | 2016 | 84 | 0.120 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 132 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2025 | 4672 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2026 | 1539 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 560 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 693 | 0.110 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2025 | 40 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2016 | 767 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2017 | 375 | 0.100 |
Why?
|
| DNA Repair | 1 | 2016 | 571 | 0.100 |
Why?
|
| Precision Medicine | 2 | 2026 | 382 | 0.090 |
Why?
|
| Graft Survival | 2 | 2025 | 460 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2025 | 2897 | 0.070 |
Why?
|
| Mutation | 2 | 2021 | 6085 | 0.070 |
Why?
|
| Transduction, Genetic | 2 | 2020 | 277 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2025 | 1920 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 393 | 0.060 |
Why?
|
| Female | 6 | 2025 | 70257 | 0.060 |
Why?
|
| Chemokine CXCL11 | 1 | 2025 | 9 | 0.060 |
Why?
|
| Middle Aged | 3 | 2025 | 28334 | 0.060 |
Why?
|
| Chemokine CXCL10 | 1 | 2025 | 52 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 993 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2025 | 1074 | 0.060 |
Why?
|
| Skin Transplantation | 1 | 2025 | 56 | 0.060 |
Why?
|
| Leukocyte Elastase | 1 | 2025 | 20 | 0.060 |
Why?
|
| Gene Knock-In Techniques | 1 | 2025 | 117 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 42 | 0.060 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2025 | 77 | 0.050 |
Why?
|
| Sepharose | 1 | 2024 | 11 | 0.050 |
Why?
|
| Male | 5 | 2025 | 64344 | 0.050 |
Why?
|
| Gene Expression | 2 | 2020 | 1486 | 0.050 |
Why?
|
| Young Adult | 1 | 2018 | 9990 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2024 | 301 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2025 | 666 | 0.050 |
Why?
|
| Tissue Scaffolds | 1 | 2024 | 82 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2024 | 108 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2023 | 14 | 0.050 |
Why?
|
| Collagen | 1 | 2024 | 274 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2025 | 373 | 0.050 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2022 | 7 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2024 | 242 | 0.050 |
Why?
|
| Neutrophils | 1 | 2025 | 361 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2022 | 32 | 0.050 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2022 | 21 | 0.050 |
Why?
|
| Phenotype | 2 | 2024 | 4465 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 464 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2024 | 316 | 0.050 |
Why?
|
| Cell Survival | 1 | 2024 | 829 | 0.040 |
Why?
|
| Proteomics | 1 | 2026 | 612 | 0.040 |
Why?
|
| Adult | 2 | 2020 | 31092 | 0.040 |
Why?
|
| Germany | 1 | 2020 | 59 | 0.040 |
Why?
|
| Disease Resistance | 1 | 2020 | 23 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2020 | 76 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 640 | 0.040 |
Why?
|
| Adolescent | 1 | 2018 | 20706 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 193 | 0.040 |
Why?
|
| Living Donors | 1 | 2020 | 111 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2459 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 347 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 218 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 331 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2020 | 160 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Models, Biological | 1 | 2024 | 1384 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 535 | 0.040 |
Why?
|
| Transgenes | 1 | 2020 | 320 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2019 | 123 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 228 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 552 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2019 | 109 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 116 | 0.040 |
Why?
|
| Lung | 1 | 2026 | 1531 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 810 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 66 | 0.030 |
Why?
|
| Transcriptome | 1 | 2024 | 1112 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 256 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 231 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1121 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1657 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1481 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2330 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12827 | 0.030 |
Why?
|
| Kidney | 1 | 2020 | 1277 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 6780 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 800 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6435 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3380 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 2010 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4660 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 20837 | 0.020 |
Why?
|